Revolutionary New Method Enhances Precision in Genome Editing Assessments

Scientists at St. Jude Children’s Research Hospital have unveiled a groundbreaking method, CHANGE-seq-BE, designed to significantly improve the assessment of precision genome editing technologies like base editors. This innovative technique offers a more sensitive, unbiased, and resource-efficient way to identify potential off-target edits, a critical factor for ensuring the safety and efficacy of gene therapies.

Key Takeaways

• A new method called CHANGE-seq-BE has been developed to assess precision genome editing technologies.
• It offers an unbiased, sensitive, and resource-efficient approach to identifying off-target edits.
• The method has already been used to support clinical work, including an FDA submission.
• CHANGE-seq-BE outperforms conventional methods in detecting off-target edits while using fewer resources.

Advancing Genome Editing Safety and Precision

Genome editing technologies, particularly CRISPR-based systems, are rapidly evolving. While CRISPR-Cas9 cuts DNA, newer tools like base editors can precisely alter individual DNA base pairs. However, a major challenge in developing these advanced tools is the meticulous identification of small, potentially harmful off-target edits. This process has historically been time-consuming and resource-intensive.

To address this, researchers at St. Jude developed CHANGE-seq-BE (Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors). This novel method provides a streamlined approach to understanding the global activity of base editors, enabling scientists to select the most specific and effective editor-target combinations for research and therapeutic applications.

Clinical Applications and Superior Performance

CHANGE-seq-BE is already making an impact in clinical settings. The technique was instrumental in supporting an emergency application to the Food and Drug Administration (FDA) for a base editor aimed at treating CD40L-deficient X-linked Hyper IgM (X-HIGM) syndrome, a genetic immune disorder. In this case, CHANGE-seq-BE confirmed a high on-target specificity of 95.4% with no significant off-target activity, providing crucial safety data for the patient’s treatment.

Dr. Shengdar Tsai, the corresponding author of the study published in Nature Biotechnology, highlighted the method’s utility: "It was a really exciting application to support an emergency request to the FDA to treat a patient rapidly. It exemplifies how this method enables rapid understanding of what these editors are doing in the genome and helps advance promising active and specific therapeutics."

Efficiency Meets Comprehensiveness

Conventional methods for assessing base editor safety often present a trade-off between comprehensive analysis and efficient resource utilization. Some techniques require expensive and time-consuming whole-genome sequencing to detect all potential off-target edits. Others pre-select suspected off-target sites to reduce sequencing costs, but risk missing unexpected edits. CHANGE-seq-BE was designed to overcome these limitations by combining comprehensive coverage with resource efficiency.

The method works by first processing the entire genome, then dividing it into small circular DNA fragments. These circles are exposed to the base editor being tested. A specialized enzyme then identifies and opens only those circles showing evidence of base editing. These linear DNA strands are then selectively sequenced, drastically reducing the resources needed compared to other methods. The technique has been optimized for both major types of base editors (adenine and cytosine) and has demonstrated superior sensitivity, detecting nearly all sites identified by other methods and many unique ones, while using approximately 5% of the sequencing reads.

Widespread Adoption and Future Promise

Due to its sensitivity, ease of use, and efficiency, CHANGE-seq-BE is rapidly being adopted by researchers and clinicians. The study provides full experimental protocols and software to facilitate its implementation. Beyond the reported clinical application, CHANGE-seq-BE is being integrated into clinical trials at St. Jude and other institutions as a vital safety and efficiency evaluation tool. It has also been used to characterize the first patient-specific in vivo genome editing treatment and is being employed by fundamental research labs to identify the most promising base editing approaches early in their development.

"We’ve enabled those developing these therapies to quickly understand and find the base editors with the highest potential activity and specificity," stated Dr. Tsai. "We hope that methods like CHANGE-seq-BE will open the door toward more genome editing therapies being developed for and reaching the patients who need them."

Sources

• New method can help better assess precision genome editing technology, News-Medical.

IntelligentHQ

Founder Dinis Guarda

IntelligentHQ Your New Business Network.

IntelligentHQ is a Business network and an expert source for finance, capital markets and intelligence for thousands of global business professionals, startups, and companies.

We exist at the point of intersection between technology, social media, finance and innovation.

IntelligentHQ leverages innovation and scale of social digital technology, analytics, news, and distribution to create an unparalleled, full digital medium and social business networks spectrum.

IntelligentHQ is working hard, to become a trusted, and indispensable source of business news and analytics, within financial services and its associated supply chains and ecosystems